Jae B. Kim, MD

New Capabilities

Appointed 2026; shepherding SHIELD-AL

The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. Protego says the study is planned to begin in the first quarter of 2027.

Updated Oct 25